This paper contributes to the field of RNA vaccinology, specifically addressing a key challenge in self-amplifying RNA (saRNA) vaccine development. While saRNA vaccines offer advantages over conventional mRNA platforms by providing longer-lasting protection at lower doses, they also trigger undesirable side effects at protective doses. These side effects stem from excessive innate immune activation driven by double-stranded RNA intermediates generated during self-replication.

Excited to announce that PreciGenome will be exhibiting at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in New Orleans, May 13-17, 2025! Join us at Booth #1818 to discover our latest innovations in: Lipid Nanoparticle (LNP) Synthesis Systems: Experience our NanoGenerator™ platform, designed for scalable, reproducible, and cost-effective LNP, liposome, and PLGA nanoparticle production-ideal for applications from early discovery to GMP manufact